Lexicon Pharmaceuticals, Inc. SEC filings LXRX
Lexicon Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 9, 2010. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 14, 2026 | — |
| D | Filing | Feb 17, 2026 | — |
| EFFECT | Filing | Aug 15, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| EFFECT | Filing | May 15, 2024 | — |
| CORRESP | Letter to the SEC | May 13, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2024 | — |
| D | Filing | Jun 20, 2023 | — |
| CT ORDER | Filing | Jun 9, 2023 | — |
| D | Filing | Aug 3, 2022 | — |
| EFFECT | Filing | Sep 14, 2021 | — |
| CORRESP | Letter to the SEC | Sep 10, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2021 | — |
| EFFECT | Filing | Nov 18, 2019 | — |
| CORRESP | Letter to the SEC | Nov 15, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2019 | — |
| CT ORDER | Filing | Apr 29, 2019 | — |
| CT ORDER | Filing | Jan 22, 2018 | — |
| CT ORDER | Filing | Dec 4, 2017 | — |
| CT ORDER | Filing | Aug 14, 2017 | — |
| D | Filing | Mar 24, 2017 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2017 | — |
| CORRESP | Letter to the SEC | Feb 2, 2017 | — |
| CORRESP | Letter to the SEC | Jan 5, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2016 | — |
| CT ORDER | Filing | Dec 20, 2016 | — |
| CT ORDER | Filing | Jun 20, 2016 | — |
| CT ORDER | Filing | Nov 18, 2015 | — |
| CT ORDER | Filing | Aug 25, 2015 | — |
| EFFECT | Filing | Dec 23, 2014 | — |
| CORRESP | Letter to the SEC | Dec 23, 2014 | — |
| CT ORDER | Filing | Dec 23, 2014 | — |
| CORRESP | Letter to the SEC | Dec 23, 2014 | — |
| D | Filing | Dec 12, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2014 | — |
| D | Filing | Dec 8, 2014 | — |
| EFFECT | Filing | Sep 12, 2014 | — |
| EFFECT | Filing | Aug 8, 2012 | — |
| D | Filing | Aug 7, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 7, 2012 | — |
| CORRESP | Letter to the SEC | Aug 6, 2012 | — |
| CORRESP | Letter to the SEC | Aug 6, 2012 | — |
| EFFECT | Filing | Nov 7, 2011 | — |
| CORRESP | Letter to the SEC | Nov 4, 2011 | — |
| CORRESP | Letter to the SEC | Aug 23, 2011 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2011 | — |
| CORRESP | Letter to the SEC | Jun 7, 2011 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2011 | — |
| CT ORDER | Filing | Apr 4, 2011 | — |
| EFFECT | Filing | Feb 11, 2011 | — |
| CORRESP | Letter to the SEC | Feb 10, 2011 | — |
| CORRESP | Letter to the SEC | Feb 8, 2011 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2011 | — |
| RW | Registration withdrawal | Jan 28, 2011 | — |
| CT ORDER | Filing | Jun 28, 2010 | — |
| D | Filing | Mar 31, 2010 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2010 | — |
| CORRESP | Letter to the SEC | Mar 9, 2010 | — |
| CORRESP | Letter to the SEC | Feb 9, 2010 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- The Woodlands, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1062822
- Former names
- LEXICON PHARMACEUTICALS, INC./DE (until Dec 5, 2014); LEXICON GENETICS INC/TX (until Apr 2, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.